Health Technology Assessment (HTA)

We have more than 20 years of experience supporting health technology assessment (HTA) submissions and payer negotiations on a global basis, in markets such as Argentina, Australia, Brazil, Canada, China, Colombia, France, Germany, Finland, Japan, Mexico, Portugal, Saudi Arabia, Scotland, Spain, Sweden, the U.K., and the United States. We also have extensive experience critically reviewing and evaluating competitors’ HTA submissions.

We understand HTA guidelines and have a thorough knowledge of market access and payer strategies. This, in combination with our expertise in indirect comparison and modeling, and our innovative approaches and analytical methodologies, allows us to develop and execute comprehensive HEOR plans to support successful HTA submissions. For example:

  • We have successfully used advanced indirect comparison methods to differentiate our clients’ products from those of competitors in multiple diseases, including ADHD, neuroendocrine tumor, diabetes, and renal cell carcinoma. The results of these studies have supported successful submission of our clients’ products in the U.K., Canada, Japan, and Australia.
  • We have used an innovative modeling approach to demonstrate that our client's product was dominant compared to the incumbent biologic, when traditional modeling strategies have failed to capture the benefit of our client's drug and showed no differentiation. The model led to the positive recommendation of our client’s product by NICE (U.K.) and CADTH (Canada).